NCT03619252View on ClinicalTrials.gov

Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

January 30, 2021

Study Completion Date

June 30, 2021

Conditions
Multiple MyelomaPneumococcal InfectionFebrile NeutropeniaPneumococcal Pneumonia
Interventions
BIOLOGICAL

Vaccination with pneumococcal conjugate vaccine (PCV13)

Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria cross-reactive material. Vaccination regimen: 3 doses monthly, with a booster dose 6 months later.

DRUG

Standard Antibacterial Prophylaxis

Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.

Trial Locations (1)

220045

Minsk Scientific Practical Center of Surgery, Transplantation and Hematology, Belarus, Minsk

All Listed Sponsors
collaborator

Belarusian State Medical University

OTHER

lead

Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology

OTHER_GOV

NCT03619252 - Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents | Biotech Hunter | Biotech Hunter